Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name LINC00152
   Synonyms CYTOR, C2orf59, LINC00152, NCRNA00152, MGC4677
   Region GRCh38_2:87454781-87636740    Sequence
   Ensembl ENSG00000222041
   RefSeq NR_024204
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name glioma
   ICD-0-3  M9380/3
   Methods qPCR, Western blot, Luciferase reporter assay etc.
   Sample glioma tissues, cell lines (U87, U251 and HEK)
   Expression Pattern up-regulated
   Function Description

Linc00152 was up-regulated in glioma tissues as well as in GSCs. Knockdown of linc00152 inhibited cell proliferation, migration and invasion, while promoted GSC apoptosis. Linc00152 regulated the malignant behavior of GSCs by binding to miR-103a-3p, which functions as a tumor suppressor.In addition, knockdown of linc00152 down-regulated forebrain embryonic zinc finger protein 1 (FEZF1),a direct target of miR-103a-3p which played an oncogenic role in GSCs.FEZF1 elevated promoter activities and up-regulated expression of the oncogenic gene cell division cycle 25A (CDC25A).CDC25A over-expression activated the PI3K/AKT pathways, which regulated the malignant behavior of GSCs.Linc00152 knockdown combined with over-expressed miR-103a-3p suppressed tumor growth and manifested high survival in nude mice.

   Pubmed ID 28651608
   Year 2017
   Title Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway.
   External Links
   Links for  LINC00152 GenBank       HGNC       lncrnadb       Noncode
   Links for  glioma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.